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This study investigated the association between synthetic ovarian hormone use [i.e.,
the oral contraceptive (OC) pill] and basal C-reactive protein (CRP), peripheral blood
immune cell subsets, and circulating pro- and anti-inflammatory cytokine concentrations
in elite female athletes. Elite female athletes (n = 53) selected in Rio Summer Olympic
squads participated in this study; 25 were taking an OC (AthletesOC) and 28 were
naturally hormonally cycling (AthletesNC). Venous blood samples were collected at rest
for the determination of sex hormones, cortisol, CRP, peripheral blood mononuclear
memory and naïve CD4+ T-cells, CD8+ T-cells and natural killer cells, as well as pro-
and anti-inflammatory cytokine concentrations. C-reactive protein concentrations were
elevated (p< 0.001) in AthletesOC (median = 2.02, IQR = 3.15) compared to AthletesNC
(median = 0.57, IQR = 1.07). No differences were reported for cortisol, cytokines,
or PBMC immune cell subsets, although there was a trend (p = 0.062) for higher
IL-6 concentrations in AthletesNC. Female Olympians had substantially higher CRP
concentrations, a marker of inflammation and tissue damage, before the Rio Olympic
Games if they used an OC. Future research should examine the potential consequences
for athlete performance/recovery so that, if necessary, practitioners can implement
prevention programs.
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INTRODUCTION
Athletes are more susceptible to illness and infection during periods of intense training and
competition (Walsh and Whitham, 2006; Gleeson, 2007), which may be compounded in an
Olympic environment. Data from the London 2012 Olympic Games found that female athletes
were 60% more likely to fall ill than male athletes, and one in five illnesses was expected to result
in absence from training/competition (Engebretsen et al., 2013). This absence is associated with
decreased performance outcomes (Drew et al., 2017a). Thus, factors that contribute to an increased
risk of infection/illness in elite female athletes must be further examined so practitioners can
implement prevention programs.
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Female sex hormones play an integral role in many
physiological pathways, including regulation of the immune
system (Schuurs and Verheul, 1990). There is evidence to suggest
that the majority of female athletes use some form of oral
contraceptive (OC) (Rechichi and Dawson, 2009), which reduces
the concentration and cyclical variability of endogenous estrogen
and progesterone (Fleischman et al., 2010). While the OC pill
may be beneficial for sportswomen by reducing menstrual cycle
variability, it is possible that the administration of synthetic sex
steroids interferes with normal immune homeostasis.
C-reactive protein (CRP) is an acute phase reactant used as
a systemic marker of inflammation and tissue damage (Pepys
and Hirschfield, 2003). Elevated CRP concentrations are also
associated with an increased risk of developing cardiovascular
disease (CVD) (Ridker et al., 2000) and diabetes mellitus
(Freeman et al., 2002). When assessing CVD risk in healthy
women, CRP thresholds of <0.5 mg.L−1 (protective), 0.5–
1.0 mg.L−1 (no risk), 1.0–3.0 mg.L−1 (intermediate risk), 3.0–
10.0 mg.L−1 (high risk), and >10.0 mg.L−1 (very high risk) have
been utilized (Cook et al., 2006; Cauci et al., 2017). Of interest,
OC use has been associated with increased CRP concentrations
in healthy female adolescents (Pirkola et al., 2010) and women
(van Rooijen et al., 2006; Cauci et al., 2008; Piltonen et al., 2012;
Sørensen et al., 2014; Cauci et al., 2017). However, only one of
these studies (Cauci et al., 2017) utilized an athletic population,
of which only 14.6% had competed at a national/international
level (n = 30). Regular OC use has also been associated with
a higher CD8+ T-cell number and lower natural killer cell
number (Auerbach et al., 2002), suggesting that it may modulate
basal immune status.
Regular physical activity promotes an anti-inflammatory
immune profile (Petersen and Pedersen, 2005; Gleeson, 2007),
and so it is possible that the effects of OC use on inflammation
differ in elite sportswomen when compared to the general
community. While evidence suggests that OC use is similarly
associated with elevated CRP concentrations in athletic women
(Cauci et al., 2017), further studies need to be performed
utilizing elite-level female athletes to confirm and extend upon
these findings. Therefore, this study measured basal CRP
and peripheral blood mononuclear cells (PBMCs), as well as
other markers of stress and inflammation (e.g., cortisol, pro-
and anti-inflammatory cytokines), to provide a snapshot of
the athletes’ inflammatory status prior to the 2016 Summer
Olympic Games in Rio.
MATERIALS AND METHODS
Elite female athletes (n = 53) preparing for the Rio 2016
Olympics participated in this study [representing a subset
of the Stay Healthy project; Phase 1 of the project is
described elsewhere (Drew et al., 2017a,b)]. Athlete demographic
information is presented in Table 1. Twenty-five athletes
were taking OC (AthletesOC) and 28 were naturally cycling
(AthletesNC); the type(s) of OC used by AthletesOC were
not specified. AthletesOC has been taking OC for 6.5 ± 3.9
y, although it should be noted that only 12 of the 25
TABLE 1 | Demographic information for AthletesOC and AthletesNC.
AthletesOC AthletesNC
Age (y) 24.7 ± 3.5 24.4 ± 4.0
Height (cm) 170.88 ± 7.64 171.78 ± 6.45
Weight (kg) 66.77 ± 7.31 69.13 ± 8.71
BMI 19.51 ± 1.60 20.08 ± 2.11
Sport
Hockey 9 2
Rowing 1 3
Soccer 5 12
Water polo 5 4
Rugby 7’s 5 5
Triathlon 0 2
OC users provided information regarding length of OC use.
Nonsteroidal anti-inflammatory use was reported by only
three athletes (AthletesNC = 1, AthletesOC = 2). Participants
completed the valid and reliable Low Energy Availability
in Females Questionnaire (LEAF-Q) (Melin et al., 2014)
and an illness questionnaire (to confirm they were healthy),
and provided a single blood sample. Ethical approval was
granted by the Australian Institute of Sport and the Griffith
University Human Ethics Committee. All athletes provided
written informed consent.
Blood samples were collected from the antecubital vein
using standard venipuncture techniques. Sample times ranged
from 8:00 a.m. to 3:00 p.m. but were consistent across each
sport (i.e., all water polo players had samples taken at ∼11:00
a.m.), resulting in a similar spread of sample times across
AthletesOC and AthletesNC. Some athletes did not train prior
to sample collection, while others performed light training or
a regular training session. However, the number of athletes
in each category was similar across groups; 50, 29, and 21%
of AthletesNC performed no training, light training, and
regular training, respectively, compared to 56, 24, and 20% of
AthletesOC. On average, AthletesNC had their blood taken 2.5 h
post-training, which was very similar to AthletesOC (2.0 h).
Blood samples were taken randomly with respect to menstrual
cycle, however, hormone concentration data (progesterone
and estradiol) were used to stratify AthletesNC according to
menstrual cycle phase using established reference values (Stricker
et al., 2006; data were converted to relevant units for comparison
where necessary).
Serum concentrations of estradiol, progesterone, and free
testosterone were determined using commercially available
enzyme-linked immunosorbent assay (ELISA) kits (Abcam,
Cambridge, United Kingdom) according to the manufacturer’s
instructions. Serum cortisol concentrations were also determined
using a commercially available ELISA kit (Abnova, Taipei City,
Taiwan) according to manufacturer’s instructions. Inter-assay
coefficients of variation were 9.7% for estradiol, 6.0% for
progesterone, 8.1% for free testosterone, and 5.1% for cortisol. All
samples were analyzed in duplicate.
Serum CRP concentrations were determined via an
immunoturbidimetric assay using commercially available
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reagents and a COBAS Integra 400 system (Roche Diagnostics,
Mannheim, Germany). Serum cytokine concentrations were
assessed using commercially available 27-plex suspension
array kits (Bio-Rad Laboratories Pty Ltd.; Hercules, CA,
United States). This panel includes key pro- (IL1β, IL6, IL-8
TNF-α) and anti-inflammatory cytokines (IL-1ra, IL-10) as
well as relevant growth factors (VEGF, PDGF) and regulatory
cytokines (IFN-γ, IL-17). Assays were completed using a
Bioplex 200 Suspension Array Reader (Bio-Rad Laboratories
Pty Ltd.) according to the manufacturer’s instructions. Standard
curves of cytokine concentration vs. fluorescence intensity
were automatically generated by the Bioplex Manager Software
(Bio-Rad Laboratories Pty Ltd.), and sample concentrations for
each cytokine were extrapolated from respective standard curves.
All samples were analyzed in duplicate and allocation of samples
from AthletesOC and AthletesNC groups were counterbalanced
between plates. The mean inter-assay coefficient of variation for
analytes included in statistical analysis was 12.7% (range: 9.9–
18.1%). Those analytes where a high proportion of samples with
concentrations below limits of detection, or where calculated
concentrations for a given analyte were based largely on
extrapolation beyond the range of the standard curve, were not
included in statistical analysis.
PBMCs were isolated as previously published (West et al.,
2016). Briefly, PBMCs were isolated by Ficoll (GE Healthcare,
United Kingdom) density gradient separation, washed twice with
PBS at 4◦C, suspended at a concentration of 1–2 × 106 cells/mL
in medium containing 10% DMSO, and cooled to −80◦C at
a rate of −1◦C per min before transfer to liquid nitrogen for
storage until assay. Cryopreserved PBMCs were thawed and
washed in with RPMI1640 (Thermo Fisher Scientific, Waltham,
MA, United States) with 10% heat-inactivated fetal bovine serum.
PBMCs were stained for mass cytometry analyses as described
(Newell et al., 2012) with the antibodies listed in Table 2.
Data were acquired on a CyTOF 2 Helios upgraded instrument
(Fluidigm, Toronto, Canada) at the Ramaciotti Facility for
Human Systems Biology, Sydney, Australia. Flow Cytometry
Standard (FCS) files were analyzed with FlowJo X 10.0.7r2
(FlowJo, LLC, Ashland, OR, United States).
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS V.24.0, Champaign, IL,
United States) and Prism v7.00 (GraphPad Software Inc., San
Diego, CA, United States). The distribution of the data was
evaluated using Shapiro-Wilk tests. All hormone and cytokine
TABLE 2 | Mass cytometry antibody panel.
Isotope Antibody Antibody source Receptor
89Y CD45 Fluidigm Cell marker
143Nd CD45RA Fluidigm CD4+ and CD8+
memory/naïve maker
145Nd CD4 Fluidigm CD4+ T-cell marker
148Nd CD16 Fluidigm NK-cell marker
149Sm CD56 Fluidigm NK-cell marker
170Er CD3 Fluidigm T-cell marker
168Er CD8 Fluidigm CD8+ T-cell marker
markers (aside from RANTES) were not normally distributed,
thus these data were analyzed using Mann Whitney U tests. These
variables were reported as median values (interquartile range;
IQR), where IQR equals the difference between the 75th and 25th
quartiles. Mass cytometry data was normally distributed and,
along with participant demographics (i.e., age, height, weight,
BMI) and RANTES, were assessed using independent samples
t-tests; these data were reported as mean ± standard deviation.
Significance was set at P < 0.05.
RESULTS
There was no difference (p > 0.05) in age, height, weight, or
BMI between AthletesNC and AthletesOC (Table 1). AthletesNC
had higher concentrations of estradiol (p < 0.001), testosterone
(p = 0.004), and progesterone (p = 0.001), but not cortisol
(p = 0.41), when compared to AthletesOC (Table 3).
Estradiol and progesterone concentrations showed that in
the AthletesNC group, 14 athletes had hormone concentrations
commensurate with the follicular phase [estradiol: 155.00
(240.00) pmol/L, progesterone: 1.52 (4.66) nmol/L], 12 athletes
had hormone concentrations commensurate with the luteal
phase [estradiol: 225.00 (225.00) pmol/L, progesterone: 74.05
(58.33) nmol/L], and two athletes had hormone concentrations
commensurate with ovulation [estradiol: 1120.00 (460.00)
pmol/L, progesterone: 3.07 (1.46) nmol/L]. There were no
differences between AthletesNC in the follicular and luteal phases
of the menstrual cycle for cortisol (p = 0.471), CRP (p = 0.643),
or any other cytokine (p > 0.05), with the exception of IL-6
(p = 0.009) and RANTES (p = 0.022). IL-6 was higher in the
luteal phase [4.90 (2.17) pg/mL] when compared to the follicular
phase [1.47 (2.57) pg/mL], whereas RANTES was elevated in the
follicular phase (10216.30 ± 2383.60 pg/mL) when compared to
the luteal phase (8156.43± 1786.71 pg/mL).
There were no differences (p > 0.05) between AthletesOC
and AthletesNC for any of the cytokines detected by the
assay, although there was a trend (p = 0.062) for higher IL-6
concentrations in AthletesNC (Table 4). Certain cytokines (e.g.,
IL-2, IL-4, IL-5, IL-7, IL-9, IL-12, IL-13, IL-15) and growth factors
(e.g., GM-CSF, MCP-1, VEGF) were below the limits of detection
for the majority of samples and were therefore not included
in the analysis.
Figure 1 shows the difference (p < 0.001) in CRP
concentrations between AthletesOC and AthletesNC. The
number of athletes in each CRP risk stratification category is also
presented (Table 5).
TABLE 3 | Hormone concentrations for AthletesOC and AthletesNC.
AthletesOC AthletesNC
Estradiol (pg/mL) 6.12 (23.92) 35.01 (40.57)
Free testosterone (pg/mL) 0.41 (0.40) 0.80 (0.88)
Progesterone (ng/mL) 0.28 (0.46) 1.14 (12.07)
Cortisol (µg/dL) 12.23 (6.85) 10.40 (6.94)
Data are presented as median (IQR).
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TABLE 4 | Comparison of cytokine concentrations between AthletesOC and
AthletesNC.
AthletesOC AthletesNC p-value
IL-1β (pg/mL) 0.91 (0.67) 1.02 (1.79) 0.229
IL-1ra (pg/mL) 30.90 (39.65) 29.06 (22.15) 0.310
IL-6 (pg/mL) 1.22 (1.60) 3.88 (3.61) 0.062
IL-8 (pg/mL) 7.11 (9.83) 10.43 (9.69) 0.662
IL-10 (pg/mL) 5.60 (3.35) 6.12 (4.20) 0.687
IL-17 (pg/mL) 154.03 (133.32) 146.59 (63.98) 0.894
TNFα (pg/mL) 26.63 (31.31) 28.40 (87.42) 0.247
IFNγ (pg/mL) 29.82 (16.84) 27.17 (16.12) 0.940
PDGF (pg/mL) 2143.33 (1464.11) 2111.94 (832.51) 0.460
RANTES (pg/mL) 9460 ± 2511.97 9259.31 ± 2261.03 0.760
IL-1ra, interleukin-1 receptor agonist; TNFα, tumor necrosis factor alpha; IFNγ,
interferon gamma; PDGF, platelet-derived growth factor; RANTES (CCL5),
regulated on activation, normal T cell expressed and secreted. Data presented
as median (IQR), except for RANTES which is presented as mean ± standard
deviation.
FIGURE 1 | Box and whisker plot of C-reactive protein (CRP) concentrations
in AthletesNC and AthletesOC. The boxes span the interquartile range (IQR),
the line depicts the median value, the whiskers represent the highest and
lowest values within a 1.5 IQR of the nearest quartile, and the circles depict
the outliers.
TABLE 5 | The proportion of AthletesOC and AthletesNC in each CRP risk
stratification category.
Risk stratification AthletesOC n (%) AthletesNC n (%)
<0.5 mg.L−1 (protective) 4 (16) 11 (39)
0.5–1.0 mg.L−1 (no risk) 4 (16) 8 (29)
1.0–3.0 mg.L−1 (intermediate risk) 8 (32) 9 (32)
3.0–10.0 mg.L−1 (high risk) 7 (28) 0 (0)
>10.0 mg.L−1 (very high risk) 2 (8) 0 (0)
Total 25 (100) 28 (100)
Immunophenotyping of PBMCs did not reveal differences
between AthletesOC and AthletesNC. Figure 2 displays the
frequency of CD4+ T-cells, memory (CD3+, CD4+, CD45RO+)
and naïve CD4+ (CD3+, CD4+, CD45RO−) CD4+ T-cells,
CD8+ (CD3+, CD8+) T-cells and memory (CD3+, CD8+,
CD45RO+) and naïve (CD3+, CD8+, CD45RO−) CD8+ T-cells,
and NK-cells (CD3-, CD20-, CD56+, HLADR−) for AthletesOC
compared to AthletesNC.
DISCUSSION
This study is the first to investigate the effect of OC use on acute
phase hormonal and systemic inflammatory parameters in elite
female athletes prior to the Olympic Games. C-reactive protein
concentrations were significantly elevated in AthletesOC when
compared to AthletesNC. Conversely, there was no difference
between the two groups for cortisol or any other marker of
immune function, although there was a trend for higher IL-6
concentrations in AthletesNC.
C-reactive protein concentrations were threefold higher in
AthletesOC compared to AthletesNC, which supports an earlier
study (Cauci et al., 2017) that reported a fourfold increase
in CRP concentrations in athletic women using an OC when
compared to non-users. Interestingly, none of the athletes in the
prior study (Cauci et al., 2017) recorded CRP concentrations
of>10.0 mg.L−1 (“very high” CVD risk) (Cook et al., 2006; Cauci
et al., 2017), whereas two OC users (8%) fell into this category
in the current cohort. Only 16% of AthletesOC had “protective”
CRP concentrations compared to 39% of AthletesNC, and 32%
of AthletesOC fell into the combined “protective” and “no risk”
categories (CRP < 1 mg.L−1) compared to 68% of AthletesNC.
It should be noted, however, that CRP is only one risk factor
for CVD (Ridker et al., 2005), and elite athletes would likely
otherwise be considered low risk for CVD given the protective
effect of regular physical activity (Li and Siegrist, 2012), low
rates of excess body mass (Wd et al., 1996), and generally good
nutritional practices (Lun et al., 2009; Heaney et al., 2011).
Nevertheless, 36% of AthletesOC had CRP values of >3 mg.L−1
compared to 0% of women in the AthletesNC group, which is
indicative of systemic inflammation in this cohort.
Previously, a higher percentage of athletes not using an OC
were observed to have CRP concentrations of <0.5 mg.L−1,
and fewer had concentrations of >3 mg.L−1, when compared
to non-OC users in the general population (Cauci et al.,
2008, 2017). Interestingly, this inverse relationship between CRP
concentration and exercise was not observed for the athletes
using an OC (Cauci et al., 2017). These findings suggest that
regular exercise decreases the frequency of high-inflammatory
status, while increasing the frequency of basal protective low-
inflammatory status, in non-OC users but not those taking
an OC (Cauci et al., 2017). Moreover, a higher percentage of
AthletesOC had CRP concentrations >3 mg.L−1 (36%) than
previously observed in OC users in the general population (31%)
(Cauci et al., 2008). It is not immediately clear as to why this
occurred, however, periods of intensified training can have an
immunosuppressive effect (Walsh and Whitham, 2006; Gleeson,
2007). Given that blood sampling occurred 3 months prior to
the Olympic Games, all athletes were performing heavy training
loads which may explain the results obtained. Indeed, 87% of
athletic women who were not taking an OC in the recent study
by Cauci et al. (2017) reported CRP concentrations of<1 mg.L−1
compared to 68% of AthletesNC in the present study, indicating
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FIGURE 2 | PBMC subsets between AthletesOC and AthletesNC. There were no significant differences between the groups in CD4+ or CD8+ T-cells (top left),
memory (CD3+, CD4+, CD45RO+) or naïve (CD4+, CD45RO−) CD4+ T-cells (top right), memory (CD3+, CD8+, CD45RO+) or naïve (CD3+, CD8+, CD45RO−)
CD8+ T-cells (bottom left), or NK-cells (CD20-, CD56+, HLADR−) (bottom right).
an increased inflammatory status even amongst non-OC users.
However, in the main, the results suggest that OC users have
elevated CRP concentrations relative to athletes who do not take
OC, with little difference between athletes and non-athletes in
terms of the CRP response to OC use.
As expected, estradiol, progesterone, and testosterone were
lower in the AthletesOC group when compared to AthletesNC
(Wiegratz et al., 2003; Fleischman et al., 2010). While no previous
research has compared cortisol concentrations in elite female
athletes according to OC status, one study found that cortisol
concentrations doubled in high school/university athletes after 10
months of OC use when compared to pre-OC levels (Rickenlund
et al., 2004). Although we did not have access to pre-OC
cortisol data, the comparable values reported for AthletesOC and
AthletesNC do not suggest a significant relationship between OC
use and basal cortisol concentrations. In non-athlete populations,
no consistent effect of OC use on resting cortisol concentration
has been observed, with some studies showing an elevation
(Timmons et al., 2005; Boisseau et al., 2013), others showing
no difference (Bonen et al., 1991; Kirschbaum et al., 1996),
and one showing a decreased concentration (Reinberg et al.,
1996) in OC users.
No between-group difference was observed in the frequency
of PBMC immune cell subsets or for any of the cytokines
measured, although IL-6 concentrations were three times higher
(p = 0.062) in AthletesNC. This was driven by significantly
higher IL-6 concentrations in AthletesNC that were in the
luteal phase at the time of blood sampling, when compared
to those that fell into the follicular phase. Indeed, a separate
analysis revealed no significant differences between AthletesNC
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in the follicular phase and AthletesOC. There is little consensus
in the literature regarding the effect of menstrual cycle phase
on IL-6 concentrations, with some studies showing elevated
concentrations in the follicular phase (Angstwurm et al., 1997),
others in the luteal phase (Konecna et al., 2000), and others
reporting no difference (O’Brien et al., 2007). Nevertheless, these
findings are interesting given that IL-6 is thought to trigger
CRP expression (Black et al., 2004), yet CRP was higher in the
AthletesOC group though this group displayed a trend for lower
IL-6 concentrations, and there was no difference in CRP between
AthletesNC in the follicular and luteal phases despite differing
IL-6 concentrations. Giraldo et al. (2008) found that OC use
improves inflammatory status in untrained women by lowering
the concentration of IL-8 and increasing the concentration of IL-
13, which was not replicated in the current findings (there was
no between-group difference in IL-8 and IL-13 concentrations
were below the limits of detection). No differences in IL-6 were
observed between OC users and non-users in this previous study
(Giraldo et al., 2008). It is important to note that almost half of the
athletes in the present study had trained prior to blood collection,
and thus, it is possible that the samples reflect a post-exercise
cytokine response. However, separate within-group analyses of
the cytokine and CRP data were performed according to training
status (trained before sample collection vs. no training before
sample collection), and no differences in IL-6 (or CRP) were
found. This suggests that it was the use of the OC, rather than
a training response, that elicited the findings observed.
Timmons et al. (2005) observed an ∼80% greater IL-6
concentration immediately post-exercise in normally-
menstruating women in the follicular phase when compared to
women using an OC, which indicates a blunted IL-6 response
in OC users. While it is speculative to suggest an influence
of OC use on the exercise-induced cytokine response in elite
athletes given an exercise protocol was not employed, future
studies should further examine the relationship between OC
use and the cytokine response to exercise in this cohort.
Although IL-6 has known inflammatory properties, increased
IL-6 concentrations after exercise inhibit pro-inflammatory (i.e.,
TNF-α) cytokines and facilitate anti-inflammatory cytokine
(i.e., IL-1ra, IL-10) production (Petersen and Pedersen, 2005),
and thus, a disruption to this process may have implications
for recovery and performance. A recent review by Peake et al.
(2017) highlights the importance of the initial pro-inflammatory
response to exercise-induced muscle injury, but notes that
these interactions must be tightly regulated to avoid prolonged
inflammation and tissue damage.
Animal and human studies demonstrate that regular exercise
alters the balance between Th-1 and Th-2 cell subsets (Yeh
et al., 2009; West et al., 2016), and initial studies indicate that
OC use alters circulating white cell subsets at certain times
of the menstrual cycle (Auerbach et al., 2002). Our findings
indicate that, in elite athletes, OC use has little effect on key
immune subsets involved in a cell mediated immune response.
It should be noted that Auerbach et al. (2002) reported cell
differences per liter of blood, while we reported cells relative
to their parent population. However, re-calculation of our data
to be comparable to the previous study (Auerbach et al., 2002)
made no difference to our results (data not shown). Thus, our
observation suggests OC use does not modify chronic exercise-
induced PBMC immune responses in elite female athletes.
This study provides unprecedented insight into the basal
immune functioning of elite athletes leading into the Olympic
Games. However, given the elite status of the subjects and the
pivotal timing of the study, it was not possible to manipulate
the athletes’ schedules to control for factors such as training
status prior to blood sampling (and the timing of blood
sampling after training, for those that did train) and diet,
which is a limitation of the study. Ideally, training status
and/or sampling time would have been strictly controlled to
ensure uniformity between groups. Nevertheless, AthletesNC
and AthletesOC were very similar with respect to the number
of athletes that trained/didn’t train in each group prior to
blood sampling, and the timing of blood sampling post-
training (2.5 vs. 2 h, respectively). Moreover, CRP and IL-
6 were the only inflammatory markers assessed that were
significantly different (or approaching statistical significance,
in the case of IL-6) between groups, and a separate analysis
of these data according to training status (trained before
sample collection vs. no training before sample collection)
found no differences in either IL-6 or CRP for AthletesNC
or AthletesOC. This suggests that the results obtained relate
to the use of OC as opposed to reflecting a post-exercise
response. An additional limitation of the study was incomplete
data pertaining to the OC type used by AthletesOC, thus
precluding understanding of how the different OC formulas
available may differentially influence inflammation. It should
also be noted that the cross-sectional study design allows
limited understanding of the influence exerted by OC on
inflammatory markers at different time points. Nevertheless, this
study highlights a substantially increased inflammatory status
in athletes taking an OC at a pivotal point in their training
(in the months immediately prior to the Olympic Games). As
suggested by Cauci et al. (2017), it is plausible that higher
basal CRP levels may result in an exacerbated inflammatory
response when exposed to physical stress or injury. Future studies
should investigate whether higher basal CRP concentrations
are associated with reduced performance and recovery in elite
female athletes.
CONCLUSION
Elite female athletes selected for Olympic squads had
substantially greater levels of CRP if they were users of an
OC. Specifically, in the months prior to the Rio Olympic Games,
AthletesOC had threefold higher CRP concentrations than
their teammates who were not taking an OC. There was also
a trend for lower IL-6 concentrations in AthletesOC which
needs to be further explored. As female sports continue to
gather momentum and public interest, future research should
examine the relationship between OC use, immune function,
and performance/recovery in elite female populations, as this
may have important implications for the athletes’ training and
recovery programs.
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